This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Melanoma has been at the forefront of the immunotherapy revolution — checkpoint inhibitors transformed survival for metastatic melanoma from months to years. In 2026, research is pushing further: CAR-T cell therapy targeting solid tumors, personalized mRNA vaccines showing durable responses, and next-generation checkpoint combinations for patients who don't respond to standard immunotherapy.
Current Standard of Care
For unresectable or metastatic melanoma, first-line treatment is typically combination ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1), or pembrolizumab monotherapy. 5-year survival rates for metastatic melanoma have improved from approximately 5% in the pre-immunotherapy era to 50%+ in patients treated with combination checkpoint inhibition — one of the most dramatic improvements in oncology history.
For BRAF V600-mutant melanoma (approximately 50% of cases), targeted therapy with BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib) provides an alternative with rapid responses but higher relapse rates than immunotherapy.
CAR-T Cell Therapy for Solid Tumors
The IMA203 trial (Immunocore) targeting the PRAME antigen demonstrated meaningful responses in melanoma patients who had progressed after multiple prior therapies including checkpoint inhibitors. This represents a breakthrough: CAR-T and T-cell receptor (TCR)-T cell therapies working in a solid tumor, overcoming the immunosuppressive tumor microenvironment that has limited cellular therapies in non-hematologic cancers.
Additional cellular therapy trials include TIL (tumor-infiltrating lymphocyte) therapy — harvesting, expanding, and reinfusing a patient's own tumor-specific T cells. Lifileucel (Amtagvi), the first FDA-approved TIL therapy, received approval for unresectable or metastatic melanoma in 2024 based on an overall response rate of 31.5% in heavily pretreated patients.
Personalized mRNA Cancer Vaccines
The KEYNOTE-942 trial (mRNA-4157/V940 + pembrolizumab vs. pembrolizumab alone) in resected high-risk melanoma showed a 44% reduction in recurrence or death — a landmark result. This individualized neoantigen vaccine is manufactured for each patient based on mutations identified in their specific tumor. Phase 3 (KEYNOTE-942P3) is now enrolling high-risk resected melanoma patients.
Next-Generation Checkpoint Approaches
LAG-3 inhibitor relatlimab combined with nivolumab (Opdualag) is approved for unresectable or metastatic melanoma. Trials are exploring TIGIT inhibitors, TIM-3 inhibitors, and combinations of three checkpoint inhibitors for patients with primary or acquired resistance to PD-1 therapy.
Intralesional therapies — injecting immunostimulatory agents directly into accessible tumors — are generating systemic (abscopal) responses in some patients. Talimogene laherparepvec (T-VEC) is approved; next-generation oncolytic viruses and TLR agonists are in trials.
Eligibility for Melanoma Trials
Eligibility varies by disease stage and prior treatment:
- Adjuvant trials: Resected high-risk Stage IIB–IV melanoma, no evidence of disease, adequate organ function
- Metastatic trials: Unresectable Stage III or Stage IV; specific prior therapy requirements vary (some require prior checkpoint inhibitor failure)
- BRAF status: Many trials stratify or require BRAF mutation testing; ensure your tumor has been tested
- Performance status: ECOG 0–1 for most trials; brain metastases may be included or excluded depending on the study